Silodosin

Silodosin
Clinical data
Trade namesUrief, Rapaflo, Silodyx, others
Other namesKAD-3213, KMD-3213
AHFS/Drugs.comMonograph
MedlinePlusa609002
Routes of
administration		By mouth
Drug classα1 blocker
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability32%
Protein binding96.6%
MetabolismLiver glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement
Elimination half-life13±8 hours[citation needed]
Excretion33.5% Kidney, 54.9% fecal
Identifiers
  • 1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]indoline-7-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.248.664 Edit this at Wikidata
Chemical and physical data
FormulaC25H32F3N3O4
Molar mass495.543 g·mol−1
3D model (JSmol)
  • FC(F)(F)COc3ccccc3OCCN[C@H](C)Cc1cc2c(c(c1)C(=O)N)N(CC2)CCCO
  • InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1 checkY
  • Key:PNCPYILNMDWPEY-QGZVFWFLSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Silodosin, sold under the brand name Urief among others, is a medication for the symptomatic treatment of benign prostatic hyperplasia.[4][5] It acts as an alpha-1 adrenergic receptor antagonist.[4][5]

The most common side effect is a reduction in the amount of semen released during ejaculation.[5]

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  2. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  3. ^ Cite error: The named reference Rapaflo CA was invoked but never defined (see the help page).
  4. ^ a b c "Rapaflo- silodosin capsule". DailyMed. 1 December 2020. Retrieved 5 March 2023.
  5. ^ a b c d "Silodyx EPAR". European Medicines Agency (EMA). 2010-01-10. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ^ Cite error: The named reference Urorec EPAR was invoked but never defined (see the help page).